Graft Versus Host Disease

Graft-Versus-Host Disease (GVHD) is a potentially serious complication that can occur after allogeneic stem cell or bone marrow transplantation, where the transplanted cells (graft) recognize the recipient's tissues (host) as foreign and mount an immune response against them. This immune reaction can lead to widespread inflammation and damage in various organs, primarily affecting the skin, liver, and gastrointestinal tract. Acute GVHD typically occurs within the first 100 days post-transplant and is characterized by skin rash, diarrhoea, and liver dysfunction. Chronic GVHD can develop later and may present with persistent skin changes, joint pain, and other autoimmune-like symptoms. The severity of GVHD can vary, ranging from mild to life-threatening. Immunosuppressive medications are often used to manage GVHD by suppressing the donor immune cells' activity. However, balancing immune suppression to control GVHD while maintaining the graft's ability to fight cancer cells (graft-versus-tumor effect) is a delicate challenge. GVHD remains a significant concern in transplantation medicine, requiring ongoing research to improve prevention and treatment strategies. Advances in understanding the immunological mechanisms involved in GVHD are essential for enhancing the overall success and safety of allogeneic transplant procedures.